6 years ago

Mogrify Secures $16M in Series A Funding for Cell Therapy Development

  • UK-based Mogrify Ltd has closed its Series A funding round, raising $16 million led by Ahren Innovation Capital, with participation from Parkwalk, 24Haymarket, and the University of Bristol Enterprise Fund III

  • The funds will be used to advance internal cell therapy programs, develop novel IP, and increase headcount.

      • ProblemHealthcare

      "Mogrify is addressing the challenge of transforming mature human cells into other cell types efficiently and safely, without using pluripotent stem cells or progenitor cells, to develop novel cell therapies."

      Solution

      "Mogrify has developed a proprietary direct cellular conversion technology to transmogrify mature human cells into any other cell type, aiming to create safe and effective cell therapies for various diseases."

      Covered on